RPS26P52

Across TCGA pan-cancer cohorts, RPS26P52 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RPS26P52’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where RPS26P52 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPS26P52 is over-expressed in tumor, although a few such as COAD and THCA show the opposite, repressed pattern.

CHOL, STAD, and COAD are the cancer types where RPS26P52 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPS26P52 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	Female	All	+0.256	<.001	2	view →
STAD	All	All	+0.199	.022	2	view →
COAD	Female	III,IV	−0.186	.007	2	view →
THCA	All	All	−0.106	.009	2	view →
KIRP	All	III,IV	+0.099	.037	2	view →
HNSC	Male	All	+0.080	.022	2	view →
LUAD	All	III,IV	−0.304	.035	1	view →
LIHC	Female	All	+0.058	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

RPS26P52–CHOL

Open the CHOL breakdown →